

AMENDMENTS TO THE SPECIFICATION

Page 1

Before line 1 of the specification (**after the Title**), please insert the following new paragraph:

-- This application is a national phase under 35 U.S.C § 371 of PCT International Application No. PCT/SE2004/002034 which has an International filing date of December 30, 2004, which designated the United States of America. In addition, this application claims priority to Application No.: 0400021-2 filed in Sweden, which was filed on January 8, 2004 and Application No.: 0400585-6, filed in Sweden, which was filed on March 9, 2004.--


Page 2

Please replace the paragraph beginning on line 7 with the following new paragraph:

-- Our co-pending, but as of the priority date unpublished PCT application WO 04/021969 discloses compounds generally of the formula I above, but wherein R² is pyrid-2-yl substituted at the 5 position with a group of the formula $-(CHR_{11})_p-E-(CHR_{11})_q-R_{10}$ where E is E is $-CH_2-$, $-CHOH-$, $-C=O-$, $-NR_9-$, $-O-$, $-S-$, $-S(=O)_2-$;
p and q are independently 0, 1 or 2, where $p+q \leq 2$;
R₁₀ is a monocyclic ring which is optionally substituted with halo, cyano, morpholinomethyl- or morpholinoketo-; and
R₁₁ is independently H, C₁-C₃ alkyl, halo substituted C₁-C₃alkyl or hydroxy. - -

Please replace the paragraph beginning on line 23 and ending on page 4 with the following new paragraph:

--In accordance with a first aspect of the invention there are provided compounds of the formula Z:



where;

A is CH or N;

R₁ is a substituent to a carbon atom in the ring containing A selected from

-S(=O)_pR_a,

where R_a is -C₁-C₄ alkyl, -OR_x, -NR_xR_x, -NHNHNR_xR_x, -NHNHC(=O)OR_x, -NR_xOH;

-C(=O)-R_b,

where R_b is -C₁-C₄-alkyl, OR_x, -NR_xR_x, -NR_xNR_xR_x, -NHC₁-C₃-alkyl-C(=O)OR_x;

-NR_xR_c,

where R_c is H, C₁-C₄ alkyl, -NR_xR_x; -C(=O)R_d, -CN,

S(=O)_pR_x

where R_d is R_d is C₁-C₄-alkyl, -OR_x, -NR_xR_x
 -C₁-C₃-alkyl-O-C₁-C₃alkylC(=O)OR_x;

-C₁-C₃-alkyl-COOR_x;

-C₁-C₃alkyl-OH or C₁-C₄ alkyl ethers or esters thereof;

-(O-C₁-C₃alkyl)_q-O-R_x;

a 5 or 6 membered aromatic ring having 1-3 hetero atoms;
p and q are independently selected from 1 or 2;
Rx is independently selected from H, C₁-C₄ alkyl, or acetyl; or a pair of Rx can together with the adjacent N atom form a pyrrolidine, piperidine, piperazine or morpholine ring;
R₂ is a substituent to a carbon atom in the ring containing A and is H, halo, cyano, C₁-C₄-alkyl, haloC₁-C₄-alkyl;
L is -O-, -S(=O)_r- or -CH₂-, where r is 0, 1 or 2;
R₃ is H, C₁-C₃ alkyl;
R₄-R₇ are independently selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, haloC₁-C₆ alkyl, C₁-C₆ alkanoyl, haloC₁-C₆ alkanoyl, C₁-C₆ alkoxy, haloC₁-C₆ alkoxy, C₁-C₆ alkyloxyC₁-C₆ alkyl, haloC₁-C₆ alkyloxyC₁-C₆ alkyl, hydroxyC₁-C₆ alkyl, aminoC₁-C₆ alkyl, carboxyC₁-C₆ alkyl, cyanoC₁-C₆ alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;
X is -(CR₈R₈')_n-D-(CR₈R₈')_m-;
T is O or S;
D is a bond, -NR₉-, -O-, -S-, -S(=O)- or -S(=O)₂-;
n and m are independently 0, 1 or 2, provided that they are not both 0 when D is a bond;
R₈ and R₈' are independently H, C₁-C₃ alkyl, haloC₁-C₃alkyl, hydroxy, or R₈ and R₈' together with their adjacent C atom is -C(=O)-
R₉ is independently H, C₁-C₃ alkyl;
and pharmaceutically acceptable salts and prodrugs thereof,
with the proviso that R₁ as -C(=O)R_b is not morpholinoketo.--

Page 4

Please replace the paragraph beginning on line 13 with the following new paragraph:

-- The currently preferred value for T is O, that is a urea derivative,
although T as S (ie a thiourea derivative) is also highly potent. - -

Page 7

Please the replace structures beginning on line 4 with the following new
structures:

